Guaifenesin in respiratory diseases Review article
Article Sidebar
Published:
Mar 31, 2020
Keywords:
guaifenesin, expectorants, cough
Main Article Content
Abstract
Guaifenesin is an expectorant drug. The use of this drug dates back to the second half of the XXth century. Clinical studies indicate the effectiveness of guaifenesin in reducing sputum viscosity and elasticity and in facilitating expectoration.
The most important application of guaifenesin include acute upper respiratory tract infection treatment, chronic bronchitis and rhinosinusitis. Due to the good efficacy, tolerability and safety most guaifenesin formulations are available over the counter.
Article Details
How to Cite
Białek-Gosk, K. (2020). Guaifenesin in respiratory diseases. Medycyna Faktow (J EBM), 13(1(46), 82-86. https://doi.org/10.24292/01.MF.0120.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ferkol T., Schraufnagel D.: The global burden of respiratory disease. An. Am. Thor. Soc. 2014; 11: 404-406.
2. US National center for Health statistics national Ambulatory Medical care Survey: 2013 State and National Summary Tables 2013.
3. Balsamo R., Lanata L.: Egan CG Mucoactive drugs. Eur. Respir. Rev. 2010; 19(116): 127-133.
4. United States Department of Health and Human Sevices. Cold, Cough, Allergy, Bronchodilator and Antihistaminie Drug products for Over-the Counter Human Use; Expectorant Drug Products for Over-the Counter Human Use; Final Monograph. 21 CFR 341. 1989 Federal Register 54: 8494-8509.
5. Polskie Towarzystwo Farmaceutyczne: Farmakopea Polska VIII. T. 2. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Warszawa 2008: 1889.
6. Kagan L., Lavy E., Hoffman A.: Effect of mode administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm. Pharmacol. Ther. 2009; 22: 260-265.
7. Vandenheuvel W.J., Sith J.L., Siber R.H.: (2-Methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man. J. Pharm. Sci. 1972; 61: 1997-1998.
8. Kaurt G., von Meyer L., Drasch G.: Investigation of guaifenesin metabolism with gas chromatography-mass spectrometry. Arch. Toxicol. 1980; 45: 149-159.
9. Yuta A., Baraniuk J.N.: Therapeutic approaches to mucus hypersecretion. Curr. Allergy Rep. 2005; 5: 243-251.
10. Seagrave J., Albrecht H., Park Y.S. et al.: Effect of guaifenesin on mucin production, rheology and mucociliary transport in differentiated human airway epithelial cells. Exp. Lung Res. 2011; 37: 606-614.
11. Chadoush S.: Objective sputum changes associated with glyceryl guaiacolate in chronic bronchial diseases. Bull. Phisiopatol. Respir. 1973; 9: 452-456.
12. Thompson M.L., Pavia D., McNicol M.W.: A preliminary study of the effect of guaiphenesin on mucociliary clearance from the human lung. Thorax. 1973; 28: 742-747.
13. Sisson J.H., Yonkers A.J., Waldman R.H.: Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest. 1995; 107: 747-751.
14. Dispingaitis P.V., Gayle Y.E.: Effect of guaifenesin on cough reflex sensitivity. Chest 2003; 124(6): 2178-2181.
15. Bennett W.D., Kala D., Duckworth H. et al.: Effect f a single 1200 mg dose Mucinex® on mucilliary and cough clearance during an acute respiratory tract infection. Respir. Med. 2015; 109: 1476-1483.
16. Parvez L., Vaidya M., Sakhardande A. et al.: Evaluation of antitussive agents in man. Pulm. Pharmacol. 1996; 9: 299-308.
17. Albrecht H., Dicpinigaitis P.V., Guenin P.E.: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infection. Multidiscip. Respir. Med. 2017; 12: 31.
18. Robinson R.E., Cummings W.B., Deffenbaugh E.R.: Effectiveness of guaifenesin as an expectorant: a cooperative double-blind study. Cur. Ther. Res. 1977; 22: 284-296.
19. Kuhn J.J., Hendley J.O., Adams K.F. et al.: Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment. Chest 1982; 82: 713-718.
20. https://indeks.mp.pl/leki.
21. Perlík F., Janku I., Kordac V.: The effect of guaiphenesin on absorption and bioavailability of paracetamol from composite analgesic preparations. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988; 26(8): 413-416.
22. Global Initiative for Chronic Obstructive Lung Diesease (GOLD); Global strategy for the Diagnostic, Management and Prevention of COPD 2019.
2. US National center for Health statistics national Ambulatory Medical care Survey: 2013 State and National Summary Tables 2013.
3. Balsamo R., Lanata L.: Egan CG Mucoactive drugs. Eur. Respir. Rev. 2010; 19(116): 127-133.
4. United States Department of Health and Human Sevices. Cold, Cough, Allergy, Bronchodilator and Antihistaminie Drug products for Over-the Counter Human Use; Expectorant Drug Products for Over-the Counter Human Use; Final Monograph. 21 CFR 341. 1989 Federal Register 54: 8494-8509.
5. Polskie Towarzystwo Farmaceutyczne: Farmakopea Polska VIII. T. 2. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Warszawa 2008: 1889.
6. Kagan L., Lavy E., Hoffman A.: Effect of mode administration on guaifenesin pharmacokinetics and expectorant action in the rat model. Pulm. Pharmacol. Ther. 2009; 22: 260-265.
7. Vandenheuvel W.J., Sith J.L., Siber R.H.: (2-Methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man. J. Pharm. Sci. 1972; 61: 1997-1998.
8. Kaurt G., von Meyer L., Drasch G.: Investigation of guaifenesin metabolism with gas chromatography-mass spectrometry. Arch. Toxicol. 1980; 45: 149-159.
9. Yuta A., Baraniuk J.N.: Therapeutic approaches to mucus hypersecretion. Curr. Allergy Rep. 2005; 5: 243-251.
10. Seagrave J., Albrecht H., Park Y.S. et al.: Effect of guaifenesin on mucin production, rheology and mucociliary transport in differentiated human airway epithelial cells. Exp. Lung Res. 2011; 37: 606-614.
11. Chadoush S.: Objective sputum changes associated with glyceryl guaiacolate in chronic bronchial diseases. Bull. Phisiopatol. Respir. 1973; 9: 452-456.
12. Thompson M.L., Pavia D., McNicol M.W.: A preliminary study of the effect of guaiphenesin on mucociliary clearance from the human lung. Thorax. 1973; 28: 742-747.
13. Sisson J.H., Yonkers A.J., Waldman R.H.: Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers. Chest. 1995; 107: 747-751.
14. Dispingaitis P.V., Gayle Y.E.: Effect of guaifenesin on cough reflex sensitivity. Chest 2003; 124(6): 2178-2181.
15. Bennett W.D., Kala D., Duckworth H. et al.: Effect f a single 1200 mg dose Mucinex® on mucilliary and cough clearance during an acute respiratory tract infection. Respir. Med. 2015; 109: 1476-1483.
16. Parvez L., Vaidya M., Sakhardande A. et al.: Evaluation of antitussive agents in man. Pulm. Pharmacol. 1996; 9: 299-308.
17. Albrecht H., Dicpinigaitis P.V., Guenin P.E.: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infection. Multidiscip. Respir. Med. 2017; 12: 31.
18. Robinson R.E., Cummings W.B., Deffenbaugh E.R.: Effectiveness of guaifenesin as an expectorant: a cooperative double-blind study. Cur. Ther. Res. 1977; 22: 284-296.
19. Kuhn J.J., Hendley J.O., Adams K.F. et al.: Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment. Chest 1982; 82: 713-718.
20. https://indeks.mp.pl/leki.
21. Perlík F., Janku I., Kordac V.: The effect of guaiphenesin on absorption and bioavailability of paracetamol from composite analgesic preparations. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988; 26(8): 413-416.
22. Global Initiative for Chronic Obstructive Lung Diesease (GOLD); Global strategy for the Diagnostic, Management and Prevention of COPD 2019.